TORONTO, ONTARIO--(CCNMatthews - March 9, 2006) - RHEOTM Procedure Shown to Preserve or Restore Vision of Patients with Dry AMD. OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) today provided an update of MIRA-1, the Company’s recently completed pivotal (phase III) clinical trial using its RHEOTM System to treat the dry form of age-related macular degeneration (“Dry AMD”).
